GDTC CytoMed Therapeutics Ltd IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1873093 · Reporting currency SGD · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: SGD | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | 324,387 | 69,501 |
| R&D expense | 2.22M | 1.91M |
| Interest expense | 20,906 | 20,313 |
| Pretax income | -4.00M | -2.52M |
| Net income | -3.98M | -2.52M |
| EPS (basic) | -0.34 | -0.22 |
| EPS (diluted) | -0.34 | -0.22 |
| Weighted avg. shares (diluted) | 11.65M | 11.54M |
| Balance sheet | ||
| Cash & equivalents | 2.10M | 4.70M |
| Receivables | 1.57M | 1.03M |
| Current assets | 3.66M | 6.00M |
| PP&E, netmay include right-of-use assets (IFRS) | 3.69M | 3.25M |
| Goodwill | 355 | 355 |
| Intangibles | 124,894 | 93,050 |
| Total assets | 7.98M | 10.07M |
| Current liabilities | 709,169 | 606,622 |
| Short-term debt | 40,847 | 37,650 |
| Long-term debt | 368,656 | 394,310 |
| Total debt | 409,503 | 431,960 |
| Total liabilities | 1.13M | 1.02M |
| Shareholders' equity | 6.54M | 8.97M |
| Net debt | -1.69M | -4.27M |
| Shares outstanding | 11.83M | 11.54M |
| Cash flow statement | ||
| Operating cash flow | -3.70M | -2.71M |
| Capital expenditure | 637,850 | 1.40M |
| Free cash flow | -4.34M | -4.11M |
| Investing cash flow | 929,283 | 1.13M |
| Financing cash flow | 208,648 | -64,892 |
| Depreciation & amortization | 371,042 | 322,164 |
| Stock-based compensation | 694,200 | — |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· Amounts are in the company's reporting currency, SGD, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.